Article

Drug-gene interactions in older patients with coronary artery disease

2024-05-16

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Older patients with coronary artery disease (CAD) are particularly vulnerable to the efficacy and adverse drug reactions, and may therefore particularly benefit from personalized medication. Drug–gene interactions (DGIs) occur when an individual’s genotype affects the pharmacokinetics and/or pharmacodynamics of a victim drug. <bold>Objectives:</bold> This study...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5f0beac6-c23f-53bf-9824-df752513e1b0
DOI: 10.21203/rs.3.rs-4310182/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Drug-gene interactions in older patients with coronary artery diseaseDOI 10.21203/rs.3.rs-4310182/v1Read

Drug-gene interactions in older patients with coronary artery disease.Semantic proximity Read

Use of pharmacogenomics in elderly patients treated for cardiovascular diseasesSemantic proximity Read

Pharmacogenomics in Cardiovascular Diseases.Semantic proximity Read

Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.Semantic proximity Read

Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews.Semantic proximity Read

Cardiovascular pharmacogenomics: current status and future directions.Semantic proximity Read

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).Semantic proximity Read

Pharmacogenomics in cardiac therapy: Personalizing treatment for heart healthSemantic proximity Read

Cardiovascular drugs and the genetic response.Semantic proximity Read

The ABCD-GENE score influences vascular event rates in both users of clopidogrel and aspirin, as well as non-users of either drug in a population-based cohort studySemantic proximity Read

Cardiovascular pharmacogenomics.Semantic proximity Read

[Pharmacogenomics for cardiovascular drugs].Semantic proximity Read